Stockreport

Intersect ENT Announces FDA Approval of Newest Steroid Releasing Implant, PROPEL® Contour, for Use in Treating the Frontal and Maxillary Sinuses

Intersect ENT, Inc.  (XENT) 
Last intersect ent, inc. earnings: 2/24 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.intersectent.com/investor-relations
PDF Approval Broadens Patient Population for Localized Drug Delivery MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (Nasdaq:XENT), a company [Read more]